Ampersand Capital Partners

Name

Ampersand Capital Partners

Legal name

Ampersand Capital Partners LLC

Website

http://www.ampersandcapital.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Private Equity / Growth Capital (Healthcare & Life Sciences)

NAICS

Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Private equity investments
• Healthcare growth capital
• Life sciences investing
• Middle market buyouts
• Portfolio company management

Headquarters

HQ city

Wellesley

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Private Equity Fund Management: Ampersand raises limited partnership funds (currently the 12th primary fund, AMP-26, closed at $1.5 billion in May 2026) and generates revenue through management fees and carried interest on investments in healthcare and life sciences companies. Investors include endowments, foundations, pension plans, insurance companies, funds of funds, and family offices.
2. Securities Offerings / Fund Capital Raises: Ampersand Partners LLC, a Delaware-based corporation, filed SEC Form D notices for exempt securities offerings in the United States, with one such offering of $45 million (approximately $18.83 million already sold) involving multiple related persons.

Pricing tiers

Go-to-market motion1 record

Core offering

Ampersand Capital Partners is a middle-market private equity firm that raises blind-pool limited partnership funds and invests the capital in founder-led healthcare and life sciences companies across Laboratory Products, Laboratory Services, Contract Manufacturing, Pharma Services, and Specialty Products. The firm generates revenue through management fees and carried interest on committed capital, deploying both majority and minority equity investments of $10-200 million in companies with $10-100 million+ in revenue and positive EBITDA.

Differentiator

Problem solved

Functional benefit

Products and services

• AMP-26 Fund (Ampersand 2026 Limited Partnership)
• Ampersand Investment Advisory Platform

Quantifiable outcome

• Raised $1.5 billion hard cap fund (AMP-26) in less than 5 months from launch in 2026
• +5 more outcomes

Named customers1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• Biologos CEO Hetal PatelcoreOthers · 5 March 2026Biologos (a portfolio company of Ampersand Capital Partners) appointed Hetal Patel as chief executive, celebrating 50 years of growth and innovation in custom sterile-filtered liquid solutions manufacturing.
• Gannet BioChem / Laysan BioflagshipStrategic or Co-development Partner · 22 January 2026Gannet BioChem, an Ampersand Capital Partners-backed specialty CDMO (Huntsville, AL), acquired Laysan Bio (Arab, Alabama) to expand activated polymer and bioconjugation capabilities, including PEG reagents, and support partners from early development through GMP manufacturing.
• Specac / Amax Precision Ltd (acquisition)flagshipStrategic or Co-development Partner · 21 January 2026Specac, Ltd. (an Ampersand portfolio company) acquired Amax Precision Ltd., a global leader in analytical instrument precision contract manufacturing headquartered in Singapore, with production facilities in Malaysia and India. The combined entity has 400+ employees across three continents and facilities in the UK, USA, Malaysia, and India.
• Julius Clinical and Peachtree BioResearch Solutions (merger)flagshipStrategic or Co-development Partner · 14 May 2025Julius Clinical and Peachtree BioResearch Solutions announced a merger to create a fully integrated global CRO with enhanced CNS capabilities, with expanded international access and expertise in managing clinical trials across Europe and North America, focusing on CNS, cardio-metabolic, renal, and rare diseases.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Water Street Healthcare Partners: Chicago-based private equity firm exclusively focused on healthcare, with deep sector knowledge across services, products, and distribution. Highly comparable to Ampersand in both sector focus and middle-market investment size, making it a direct competitor for healthcare deals.
• Linden Capital Partners: Chicago-based private equity firm focused exclusively on the healthcare industry, including healthcare services, products, and distribution. Similar middle-market focus and healthcare-exclusive mandate as Ampersand, competing for similar platform investments.
• Bain Capital Life Sciences: Life sciences-focused investment platform of Bain Capital investing across biotech, pharma services, and medical devices. Direct competitor in life sciences PE with similar sector focus, though typically at larger deal sizes than Ampersand.
• GHO Capital Partners: European healthcare and life sciences specialist PE firm with offices in London and Amsterdam. Closely comparable to Ampersand's European healthcare focus and was the acquirer of Alcami (an Ampersand exit) in 2022, making it a direct competitor in European life sciences deals.
• Welsh, Carson, Anderson & Stowe: Healthcare-focused PE firm with deep sector expertise across services, products, and technology-enabled healthcare. Comparable to Ampersand's healthcare-exclusive focus, though typically operating at larger fund sizes and broader service line scope.
• New Mountain Capital: Growth-oriented private equity firm with significant healthcare and life sciences focus, including pharma services, CDMOs, and healthcare technology. Comparable to Ampersand in growth-stage healthcare investing approach, though at larger scale.
• GTCR LLC: Chicago-based private equity firm with strong healthcare sector presence and Leaders Strategy approach of partnering with C-level executives. Comparable to Ampersand in healthcare services and products focus with similar mid-market deal sizes.
• Avista Capital Partners: Healthcare-focused private equity firm founded in 2005 that invests in healthcare products, services, and pharmaceuticals. Closely comparable to Ampersand in healthcare-exclusive focus, mid-market deal sizes, and operational value-add approach.

Broad incumbents

• TPG Capital: Large alternative asset manager with dedicated healthcare investing through TPG Capital Healthcare and TPG Life Sciences. Broader incumbent competing with Ampersand for healthcare deals, including having acquired a majority stake in Confluent Medical (an Ampersand portfolio exit in 2022).
• KKR: Global investment firm with a substantial healthcare and life sciences practice. Larger incumbent competing for healthcare deals at the upper end of the market; potential co-investor or competitor depending on deal size and structure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xlinkedin.com/company/ampersand-capital-partners
• YouTubeyoutube.com/@AmpersandCapitalPartners
• LinkedInlinkedin.com/company/ampersand-capital-partners

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries27 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A19 records

Investments78 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ampersand Capital Partners